Preddator Low-volume Microplate Dispenser Awarded ELRIG Prize
News Jul 10, 2013
Redd&Whyte has announced that its innovative Preddator low-volume microplate dispenser has been awarded the “ELRIG Technology Prize”, which recognizes the most interesting automation seen at the recent ELRIG Robotics and Automation Conference.
The award was voted for by delegates at the ELRIG Robotics and Automation show, in recognition of the fact that the Redd&Whyte Preddator nano dispenser has a unique design that is capable of precisely dispensing a wide range of fluid types and cell suspensions into any microplate format from 96-3456 wells.
The Preddator is an ideal research tool for a wide range of applications including: assay development, protein dispensing, DMSO backfilling, silicon oil deposition and PCR master mix preparation.
The system can be used as a stand-alone system or can be integrated into a range of different automated assay preparation and screening systems.
This award winning version of the Preddator is currently in operation at several of the top 10 pharma companies, where it is being successfully used in compound screening groups where consistency of assay data and reduction in assay costs are critical.
Roger Poole, Managing Director of Redd&Whyte said: “Redd&Whyte is honoured to be chosen for this prestigious ELRIG award. For the Preddator system to be acknowledged for liquid handling innovation alongside products from some of the world’s top automation firms is a great endorsement. This is a competition judged by ELRIG delegates and as such is very valuable recognition of the unique contribution Preddator can make to any compound screening workflow.”
Children With Congenital Zika Virus Infection Face Serious Challenges as They AgeNews
The report from the CDC is the first to describe the health and developmental effects of congenital Zika virus infection in children with microcephaly through 2 years of age.READ MORE
British Pharmacological Society’s Drug Discovery of the Year 2018 AnnouncedNews
A new medicine used to treat an ultra-rare inherited disorder which leaves babies without a fully functioning immune system has been named the British Pharmacological Society’s Drug Discovery of the Year 2018.READ MORE